DNA Capital

United States
Firm Location:United States • Minneapolis, Minnesota • Palo Alto, California • Rio De Janeiro, Brazil • Sao Paulo, Brazil
Investor Firms That Co-Invest with DNA Capital
DNA Capital Team
Photo of Adam Alves, Partner at DNA Capital
Adam Alves
DNA Capital·Partner
Sweet spot: $2.5M
Range: $100K - $5.0M
Investors in Sao Paulo (Brazil)
Investors in Medical Devices (Seed), Investors in Consumer Health (Series B), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Consumer Health (Series A), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Consumer Health (Seed), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series A), Investors in Health IT (Series A), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series B), Investors in BioTech (Series A), Investors in Consumer Health (Series A), Investors in Medical Devices (Seed), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Health IT (Seed), Investors in Pharmaceuticals (Seed), Investors in Consumer Health (Seed), Investors in Consumer Health (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Series B), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
Photo of Carlos de Barros, Partner at DNA Capital
Carlos de Barros
DNA Capital·Partner
Sweet spot: $2.5M
Range: $100K - $5.0M
Investors in Sao Paulo (Brazil)
Investors in Medical Devices (Seed), Investors in Consumer Health (Series B), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Consumer Health (Series A), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Consumer Health (Seed), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series A), Investors in Health IT (Series A), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series B), Investors in BioTech (Series A), Investors in Consumer Health (Series A), Investors in Medical Devices (Seed), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Health IT (Seed), Investors in Pharmaceuticals (Seed), Investors in Consumer Health (Seed), Investors in Consumer Health (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Series B), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
Photo of Pedro Bueno, Partner at DNA Capital
Pedro Bueno
DNA Capital·Partner
Sweet spot: $2.5M
Range: $100K - $5.0M
Investors in Sao Paulo (Brazil)
Investors in Medical Devices (Seed), Investors in Consumer Health (Series B), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Consumer Health (Series A), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Consumer Health (Seed), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series B), Investors in Pharmaceuticals (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Health IT (Pre-seed), Investors in Consumer Health (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series A), Investors in Health IT (Pre-seed), Investors in Health IT (Series A), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series B), Investors in BioTech (Series A), Investors in Consumer Health (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Health IT (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health & Hospital Services (Seed), Investors in Pharmaceuticals (Seed), Investors in Consumer Health (Seed), Investors in Consumer Health (Series B), Investors in Medical Devices (Pre-seed), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Consumer Health (Pre-seed), Investors in Medical Devices (Series B), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Series A), Investors in Medical Devices (Seed), Investors in Digital Health (Series B), Investors in BioTech (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
Photo of Lucas Cortez, Associate at DNA Capital
Lucas Cortez
DNA Capital·Associate
Sweet spot: $2.5M
Range: $100K - $5.0M
Investors in Sao Paulo (Brazil)
Photo of Luiz Felipe D Martins Costa, Partner at DNA Capital
Luiz Felipe D Martins Costa
DNA Capital·Partner
Sweet spot: $2.5M
Range: $100K - $5.0M
Investors in Sao Paulo (Brazil)
Photo of José Eduardo Ribeiro Guinle, Partner at DNA Capital
José Eduardo Ribeiro Guinle
DNA Capital·Partner
Sweet spot: $2.5M
Range: $100K - $5.0M
Investors in Sao Paulo (Brazil)
Photo of Thayan Hartmann, Partner at DNA Capital
Thayan Hartmann
DNA Capital·Partner
Sweet spot: $2.5M
Range: $100K - $5.0M
Investors in Sao Paulo (Brazil)
Photo of Partha Mishra, Partner at DNA Capital
Partha Mishra
DNA Capital·Partner
Sweet spot: $2.5M
Range: $100K - $5.0M
Investors in Sao Paulo (Brazil)
Photo of Luiz Noronha, Partner at DNA Capital
Luiz Noronha
DNA Capital·Partner
Sweet spot: $2.5M
Range: $100K - $5.0M
Investors in Sao Paulo (Brazil)
Investors in Consumer Health (Series B), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Consumer Health (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in FinTech (Series B), Investors in Consumer Health (Seed), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in SaaS (Series B), Investors in Health & Hospital Services (Series A), Investors in San Francisco Bay Area (Other Lists), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series A), Investors in Health IT (Series A), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series B), Investors in BioTech (Series A), Investors in Consumer Health (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in FinTech (Series B), Investors in Health IT (Seed), Investors in SaaS (Seed), Investors in Health & Hospital Services (Seed), Investors in Pharmaceuticals (Seed), Investors in Consumer Health (Seed), Investors in Consumer Health (Series B), Investors in SaaS (Series B), Investors in SaaS (Series A), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Series A), Investors in FinTech (Seed), Investors in FinTech (Series A), Investors in Digital Health (Series B), Investors in SaaS (Series A), Investors in Health IT (Seed), Investors in FinTech (Series A), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in FinTech (Seed), Investors in Health & Hospital Services (Seed), Investors in SaaS (Seed)
Photo of Julia Prado, Analyst at DNA Capital
Julia Prado
DNA Capital·Analyst
Sweet spot: $2.5M
Range: $100K - $5.0M
Investors in Sao Paulo (Brazil)
Investors in Consumer Health (Series B), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Consumer Health (Series A), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in Consumer Health (Seed), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series B), Investors in Consumer Health (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Seed), Investors in Health IT (Series A), Investors in Consumer Health (Seed), Investors in Consumer Health (Series B), Investors in Health IT (Seed), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Series B), Investors in Health & Hospital Services (Series A), Investors in Medical Devices (Seed), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
Photo of Mitesh Rao, Venture Partner at DNA Capital
Mitesh Rao
DNA Capital·Venture Partner
Sweet spot: $2.5M
Range: $100K - $5.0M
Investors in Sao Paulo (Brazil)
Photo of Mario Sergio Ribeiro, Partner at DNA Capital
Mario Sergio Ribeiro
DNA Capital·Partner
Sweet spot: $2.5M
Range: $100K - $5.0M
Investors in Sao Paulo (Brazil)
Investors in Medical Devices (Seed), Investors in Consumer Health (Series B), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Consumer Health (Series A), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Consumer Health (Seed), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series A), Investors in Health IT (Series A), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series B), Investors in BioTech (Series A), Investors in Consumer Health (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Health IT (Seed), Investors in Pharmaceuticals (Seed), Investors in Consumer Health (Seed), Investors in Consumer Health (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in Medical Devices (Series B), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Series A), Investors in Medical Devices (Seed), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
Photo of Sergio Ricardo Santos, Partner at DNA Capital
Sergio Ricardo Santos
DNA Capital·Partner
Sweet spot: $2.5M
Range: $100K - $5.0M
Investors in Sao Paulo (Brazil)
Investors in Consumer Health (Series B), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in Consumer Health (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in Consumer Health (Seed), Investors in Pharmaceuticals (Series A), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series B), Investors in Pharmaceuticals (Pre-seed), Investors in Health IT (Pre-seed), Investors in Consumer Health (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series A), Investors in Health IT (Pre-seed), Investors in Health IT (Series A), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series B), Investors in BioTech (Series A), Investors in Consumer Health (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Health IT (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health & Hospital Services (Seed), Investors in Pharmaceuticals (Seed), Investors in Consumer Health (Seed), Investors in Consumer Health (Series B), Investors in BioTech (Seed), Investors in Consumer Health (Pre-seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series B), Investors in BioTech (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
Photo of Suzie Kim Yoon, Associate at DNA Capital
Suzie Kim Yoon
DNA Capital·Associate
Sweet spot: $2.5M
Range: $100K - $5.0M
Investors in Sao Paulo (Brazil)